Weight Management Strategies Explained in Clinical Application

Discover how clinical weight management applications can support your journey toward better health and wellness.

Abstract

Welcome to our educational post on metabolic health and advanced weight management strategies. I’m Dr. Alex Jimenez, and today we’ll embark on a journey into the complex world of obesity—a chronic, relapsing, multifactorial disease that is often misunderstood. In this educational post, I will present an up-to-date, evidence-based overview of how pharmacologic therapies, functional medicine, and integrative chiropractic strategies can be combined within a medically directed, team-based model to improve outcomes. We will explore the latest pharmacological treatments, moving beyond outdated notions and focusing on modern scientific understanding. This discussion will cover the physiological underpinnings of conditions like binge eating disorder, the mechanisms of action for various weight management medications, including the revolutionary GLP-1 agonists, and how to tailor these treatments to individual patient needs. At Injury Medical Clinic, our multidisciplinary team, under the medical direction of Dr. Maria Guadalupe Cardenas, MD, combines cutting-edge medical treatments with functional medicine, chiropractic care, and rehabilitation to address the root causes of metabolic dysfunction and support long-term, sustainable health. Join me as we delve into these topics and empower you with the knowledge to navigate your own health journey.

Our Integrative and Collaborative Care Model

Before we dive into the specifics of metabolic health, I want to take a moment to introduce our unique clinical model here at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. I am Dr. Alex Jimenez, and my credentials include DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST. My passion has always been to provide comprehensive, patient-centered care that addresses the whole person, not just a set of symptoms.

To achieve this, our practice is built on a foundation of multidisciplinary collaboration. I am honored to work alongside Dr. Maria Guadalupe Cardenas, MD, who serves as our Medical Director and Collaborative Physician. Dr. Cardenas is a highly respected, board-certified internist with over 40 years of invaluable experience (NPI #1164426749, Texas MD License #J2933). Her deep knowledge of internal medicine provides essential medical oversight, safety, and evidence-based alignment with internal medicine standards across our programs, ensuring our patients receive the safest and most effective care possible.

This collaborative structure allows us to blend the best of different worlds:

• Medical Oversight (Dr. Cardenas): Provides diagnosis, prescription management, medical evaluation of cardiometabolic risk, multimorbidity, and medication safety. Dr. Cardenas is responsible for the diagnostic workup, selection, and monitoring of anti-obesity pharmacotherapy, and she oversees our care pathways, coordinating with endocrinology, bariatric surgery, behavioral health, and primary care when needed.
• Integrative Chiropractic and Functional Medicine (Dr. Jimenez): I focus on the musculoskeletal system, nervous system function, and biomechanics. Chiropractic care addresses the spine, joints, and soft tissues to reduce pain, improve mobility, and restore neuromuscular function. Concurrently, my functional medicine assessments identify metabolic drivers—such as insulin resistance, inflammation, sleep, stress, and microbiome diversity—to create individualized care plans. We also develop rehabilitation protocols to support movement re-education and strength restoration, crucial for sustainable weight loss and injury prevention.
• Comprehensive Services: Our offerings include personal injury care, physical rehabilitation, nutrition counseling, and advanced metabolic health programs.

By integrating these disciplines, we create a synergistic effect where each therapy enhances the others, leading to superior patient outcomes. A patient undergoing a medical weight management program also benefits from chiropractic care to address joint pain from excess weight, functional medicine to balance hormones, and rehabilitation to build strength safely. Obesity is a chronic disease with neurobehavioral, neuroendocrine, metabolic, and biomechanical components; no single discipline suffices. This is the essence of true integrative healthcare. I regularly share clinical insights and frameworks, which you can find through my clinical observations at dralexjimenez.com and professional updates at linkedin.com/in/dralexjimenez.

Understanding Obesity as a Chronic, Relapsing Disease

We treat obesity as a disease—not a character flaw. The science is unequivocal: obesity is chronic, progressive, and relapsing, shaped by genetics, epigenetics, neuroendocrine signaling, environment, and social determinants of health (SDOH) (Garvey & Mechanick, 2020; Wharton et al., 2020). When effective medications are stopped, weight typically rebounds, just as hypertension worsens after stopping antihypertensives. That relapse reflects biology, not failure.

Key Disease Characteristics

• Chronicity: It involves sustained dysregulation in appetite, energy expenditure, and adipose tissue function.
• Relapse: Powerful adaptive neurohormonal counterregulation promotes weight regain after loss, a biological defense mechanism (Sumithran & Proietto, 2013).
• Multifactorial: It is driven by a complex interplay among genetic variants; hormones such as leptin, ghrelin, GLP-1, GIP, and cortisol; environmental factors such as ultra-processed foods and sedentary behavior; psychosocial stressors; and SDOH (Hruby & Hu, 2015).

Physiological Underpinnings

• Hypothalamic Circuitry: The brain’s hypothalamic arcuate nucleus acts as a control center. It contains two key sets of neurons: POMC/CART neurons, which decrease appetite, and AgRP/NPY neurons, which increase it. This center integrates peripheral signals from hormones like leptin (from fat cells), insulin (from the pancreas), GLP-1 (from the gut), and ghrelin (from the stomach) to precisely modulate appetite and energy expenditure (Morton et al., 2014). In obesity, this signaling becomes dysregulated.
• Adipose Tissue Dysfunction: Healthy adipose (fat) tissue is an active endocrine organ. However, when fat mass expands excessively, it becomes inflamed. This “adiposopathy” leads to the recruitment of immune cells like macrophages, which then secrete pro-inflammatory cytokines such as TNF-α and IL-6. These cytokines, along with increased release of free fatty acids, spill over into the circulation and contribute directly to systemic insulin resistance and cardiometabolic diseases such as type 2 diabetes and heart disease (Ouchi et al., 2011).
• Set-Point Defense: The body has a biologically defended “set point” for body weight. When we lose weight, the body perceives this as a threat to survival. It fights back by increasing hunger hormones (like ghrelin) and decreasing satiety hormones. Simultaneously, it reduces resting energy expenditure to conserve energy. This powerful defense mechanism, an evolutionary relic, makes weight regain highly likely and provides a strong rationale for using long-term pharmacotherapy and structured lifestyle support to counteract it (Rosenbaum & Leibel, 2010).

Clinical Implications

• Expect relapses and plan for long-term maintenance from the beginning.
• Combine pharmacologic and non-pharmacologic modalities to address the multifaceted nature of the disease.
• Address social determinants of health and weight bias to improve access to care and adherence.

Understanding Binge Eating Disorder (BED)

A critical component of understanding obesity is recognizing the psychological and behavioral factors that often accompany it. One of the most common is binge eating disorder (BED). This isn’t simply “overeating”; it’s a recognized medical condition with specific diagnostic criteria. BED is characterized by recurrent episodes of eating an amount of food in a discrete period that is definitively larger than what most people would eat under similar circumstances. A key feature is a profound sense of lack of control during the episode.

These episodes are also associated with three or more of the following behaviors:

• Eating much more rapidly than normal.
• Eating until feeling uncomfortably full.
• Eating large amounts of food even when not feeling physically hungry.
• Eating alone due to embarrassment over the quantity of food being consumed.
• Feeling disgusted, depressed, or very guilty after an episode.

From my clinical experience, particularly during my time working in bariatrics, I can attest that a significant number of patients seeking help for obesity described these exact symptoms. The distress associated with binge eating is marked and significant. For a formal diagnosis, these episodes must occur, on average, at least once a week for three months. It’s crucial to differentiate this from occasional overindulgence. Many patients report secretive eating patterns, such as waking up in the middle of the night, to hide the behavior from family, only to be overwhelmed by shame and guilt the next morning. Importantly, BED is not associated with the recurrent, inappropriate compensatory behaviors (like self-induced vomiting) seen in bulimia nervosa.

Social Determinants, Weight Bias, and Clinical Inertia

Excess body weight clusters where access to quality food, safe outdoor spaces, health literacy, and consistent medical care is limited. Economic instability and food deserts steer families toward calorie-dense, nutrient-poor options. Unsafe neighborhoods and long work hours reduce activity. These are not individual failings but systemic problems.

Weight Bias Harms Care

Implicit and explicit bias from healthcare providers can lead to underdiagnosis, undertreatment, and patient avoidance of care (Phelan et al., 2015). The psychological harm is profound; weight stigma independently predicts worse cardiometabolic profiles, depression, and even mortality, beyond the effects of BMI alone (Tomiyama et al., 2018).

Clinical Inertia

Although effective therapies exist, very few patients receive anti-obesity pharmacotherapy or timely referral for surgery when appropriate. Barriers within the healthcare system, such as insurance coverage limits and prior authorizations, coupled with clinical time constraints and insufficient training, all contribute to this inertia (Shah et al., 2021).

Our approach is to normalize obesity as a disease and discuss the full spectrum of options without stigma. We use structured counseling frameworks like Ask-Assess-Advise-Agree-Assist/Arrange and engage in shared decision-making to align goals with patient values and resources (Jensen et al., 2014).

A Modern Pharmacological Toolkit for Weight Management

When we choose pharmacotherapy, our goals are to reduce hunger, improve satiety, modulate reward signaling, and counter the metabolic adaptation that causes weight regain. Dr. Cardenas oversees all medication selection, safety screening, titration, and monitoring in accordance with established guidelines, which typically indicate treatment for individuals with a BMI ≥30 kg/m² or a BMI ≥27 kg/m² with weight-related comorbidities (ADA, 2024; Apovian et al., 2022). Medications are transformative because they address the neurohormonal drivers of appetite, making lifestyle changes more achievable and sustainable. A 5–10% weight loss yields clinically meaningful benefits, a benchmark many modern agents easily surpass (Ryan et al., 2016).

Here are some key options in our toolkit:

• GLP-1 Receptor Agonists (Liraglutide, Semaglutide): These are injectable medications that mimic a gut hormone called GLP-1. Their mechanism is threefold: they enhance satiety by acting on hypothalamic pathways, slow gastric emptying to prolong feelings of fullness, and improve glycemic control. Their use is associated with significant reductions in cardiometabolic risk factors (Wilding et al., 2021).
• Dual GIP/GLP-1 Receptor Agonist (Tirzepatide): This is the next evolution, targeting both GLP-1 and a second incretin hormone, GIP. This dual action appears to produce a synergistic, more powerful effect, leading to profound, substantive weight loss that has been shown to exceed that of GLP-1 monotherapy in clinical trials (Jastreboff et al., 2022).
• Naltrexone/Bupropion (Contrave): This combination medication targets the brain’s reward and appetite-regulating centers. Bupropion stimulates appetite-reducing POMC neurons, while naltrexone blocks an inhibitory feedback loop, sustaining POMC activity and helping control cravings and reward-driven eating (Greenway et al., 2010). It can be particularly beneficial for patients who also struggle with depression or food cravings.
• Phentermine/Topiramate (Qsymia): A well-known combination drug. Phentermine is a stimulant that acts as an appetite suppressant. At the same time, topiramate’s exact mechanism is complex but is known to modulate appetite and hedonic (pleasure-seeking) aspects of eating (Gadde et al., 2011). It is effective but requires careful monitoring of heart rate and blood pressure and is teratogenic, meaning it can cause congenital disabilities, so it is absolutely contraindicated in women who are pregnant or planning to become pregnant.
• Orlistat (Xenical, Alli): This medication works differently, by inhibiting fat absorption in the gut. It blocks gastrointestinal lipases, preventing about 30% of dietary fat from being absorbed. This not only creates a caloric deficit but also serves as a behavioral feedback tool, as eating high-fat meals can cause unpleasant GI side effects (Torgerson et al., 2004).
• Lisdexamfetamine (Vyvanse): This is not an anti-obesity drug per se, but it is FDA-approved for the treatment of moderate-to-severe BED. It works by modulating neurotransmitters like dopamine and norepinephrine, which play a role in impulse control and focus, thereby reducing the frequency and intensity of bingeing episodes (McElroy et al., 2015).

A foundational step in our practice is to audit the current medication list for obesogenic agents that promote weight gain (e.g., sulfonylureas, certain antidepressants, corticosteroids). When clinically appropriate, we work to substitute these with weight-neutral or weight-lowering alternatives, as removing these pharmacological drivers enhances the effectiveness of any new therapy.

---

Discovering the Benefits of Chiropractic Care- Video

---

Integrative Chiropractic Care Within Obesity Treatment

You might wonder how chiropractic care fits into a discussion about metabolic medications. The connection is profound and synergistic. Biomechanics and pain are often the gatekeepers to physical activity. Excess adiposity increases axial and peripheral joint loads, alters gait, and stresses intervertebral discs and facet joints. This pain then reduces movement, which in turn decreases energy expenditure and muscle mass, worsening metabolic health. Breaking this vicious cycle is central to my role.

• Reducing Mechanical Stress and Pain: Excess weight places enormous strain on the musculoskeletal system. Chiropractic adjustments can restore proper joint alignment and mobility, alleviate pain, and improve function. By making movement more comfortable, we empower patients to engage in the exercise that is so critical for metabolic health.
• Enhancing Nervous System Function: The nervous system is the body’s master controller. Spinal misalignments, or subluxations, can interfere with nerve signaling. Chiropractic care aims to correct these interferences, promoting optimal nervous system function. This can have downstream effects on the very systems we are targeting with medication, such as the gut-brain axis that controls appetite. Adjustments may modulate segmental and supraspinal pain processing, improving motor control and proprioception, which supports safer activity progression (Bialosky et al., 2018).
• A Holistic Perspective and Rehabilitation: As a chiropractor and functional medicine practitioner, I view the body as an interconnected system. We blend chiropractic care with corrective exercise: hip/knee alignment, core stabilization, gluteal activation, and thoracic mobility to optimize mechanics. As a patient on a GLP-1 agonist loses weight, their posture and biomechanics shift. Chiropractic care helps the body adapt to these changes, preventing new patterns of strain and injury. When pharmacotherapy curbs hunger and improves satiety, patients can adhere to nutrition plans. And when chiropractic/rehab reduces pain, they can execute the movement portion—together, this synergy amplifies results.

Clinical observations from our practice consistently show that patients who receive coordinated chiropractic care and graded rehabilitation are more likely to hit daily step targets and progress to strength training—two pillars of durable weight loss and cardiometabolic improvement. I discuss related cases and frameworks at dralexjimenez.com.

Personalized Treatment Pathways and Clinical Cases

There is no one-size-fits-all solution. In our clinic, Dr. Cardenas and I develop individualized plans based on a comprehensive assessment that includes labs, a musculoskeletal evaluation, and screening for SDOH, eating patterns, sleep, and stress. We set realistic goals—typically 5–10% weight loss over 6 months—and choose therapies that align with the patient’s unique physiology and comorbidities.

Case Study 1: The Diabetic Patient with Stubborn Weight

Let’s consider a 45-year-old male with hypertension, type 2 diabetes, and hyperlipidemia. He has tried diet and exercise but is unable to lose weight. His current medication list includes glyburide, a sulfonylurea.

• First, Do No Harm: Glyburide is an obesogenic medication—it promotes weight gain by increasing insulin levels. Continuing it is counterproductive.
• Our Integrated Approach:

1. Discontinue the Obesogenic Medication: The first step is to stop the glyburide.
2. Optimize Existing Medications: We ensure he is on a therapeutic dose of metformin (typically 1,000 mg twice a day).
3. Introduce a Synergistic Medication: For this patient, a GLP-1 receptor agonist is an ideal choice. We prescribed semaglutide. Because he has a diagnosis of type 2 diabetes, his insurance is much more likely to cover the version branded for diabetes (Ozempic), even though it is the same medication as the one for obesity (Wegovy). This treats his diabetes and obesity simultaneously.

Case Study 2: Prediabetes, Hypertension, and Depression

Our second case is a 38-year-old male with a BMI of 34, hypertension, prediabetes, and depression. He feels his weight gain is negatively impacting his mental health.

• Our Integrated Approach:

1. Confirm Diagnosis for Coverage: A GLP-1 agonist would be excellent to address his weight and prediabetes. We would conduct thorough lab work (A1c and fasting glucose) to secure a formal diabetes diagnosis, if applicable, which would improve insurance coverage.
2. Consider a Dual-Purpose Medication: An outstanding option for this patient is naltrexone-bupropion (Contrave). The bupropion component is an effective antidepressant, while the combination effectively targets appetite and cravings. This single medication addresses his depression and promotes weight loss, which in turn will improve his blood pressure and insulin sensitivity.

Case Study 3: Binge Eating Disorder and Anxiety

Our third patient is a 32-year-old female with a BMI of 31, mild hypertension, anxiety, and a formal diagnosis of binge eating disorder (BED).

• Our Integrated Approach:

1. Target the Core Issue: For this specific presentation, we prescribed lisdexamfetamine (Vyvanse). It is the only medication with FDA approval for moderate to severe BED and works by improving impulse control and focus.
2. Navigating the Anxiety Comorbidity: While prescribing a stimulant to a patient with anxiety seems counterintuitive, many patients find that by reducing the chaotic mental state that fuels bingeing, Vyvanse can have an overall calming effect. Close monitoring is essential to ensure the treatment is helping, not harming.

Key Takeaways

The need to normalize and treat obesity with the same rigor as diabetes or hypertension has never been clearer. New pharmacologic tools are powerful, but they are most effective in a model that respects physiology, addresses stigma, and coordinates care.

• Obesity is a chronic, relapsing, multifactorial disease; long-term strategies are necessary.
• Modern agents—especially GLP-1 and GIP/GLP-1 receptor agonists—produce clinically significant weight loss when combined with lifestyle support.
• Integrative chiropractic care reduces pain and improves movement, enabling sustainable activity and synergy with pharmacotherapy.
• Medical direction from an experienced internist like Maria Guadalupe Cardenas, MD, ensures the safety, appropriate selection, and monitoring of medications.
• Addressing weight bias and SDOH is essential to delivering equitable, effective care.
• A 5–10% weight loss over 6 months is a strong initial goal, with structured reassessment and maintenance planning.

References

• American Diabetes Association. (2024). Standards of medical care in diabetes—2024. Diabetes Care.
• Allison, D. B., et al. (2009). Antipsychotic-induced weight gain: a comprehensive research synthesis. Molecular Psychiatry, 14(9), 839–851.
• Apovian, C. M., et al. (2022). Pharmacological management of obesity: An Endocrine Society guideline update. Journal of Clinical Endocrinology & Metabolism, 107(12), 3691–3720.
• Bialosky, J. E., et al. (2018). A theoretical framework for manual therapy effects: a neurophysiological perspective. Pain, 159(1), 1–10.
• Cusi, K. (2016). Treatment of NAFLD in patients with T2DM. Diabetes Care, 39(3), 308–318.
• Gadde, K. M., et al. (2011). Effects of low-dose, controlled-release phentermine plus topiramate on weight and associated comorbidities. NEJM, 365(21), 1969–1979.
• Garvey, W. T., & Mechanick, J. I. (2020). Clinical practice guidelines for obesity in adults. Obesity, 28(7), 1185–1186.
• Greenway, F. L., et al. (2010). Rational design of a combination medication for obesity: naltrexone and bupropion. International Journal of Obesity, 34(8), 1327–1336.
• Hruby, A., & Hu, F. B. (2015). The epidemiology of obesity: a big picture. International Journal of Obesity, 39(3), 395–403.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
• Jensen, M. D., et al. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 129(25 Suppl 2), S102–S138.
• McElroy, S. L., et al. (2015). Lisdexamfetamine in binge-eating disorder. JAMA Psychiatry, 72(3), 235–246.
• Morton, G. J., et al. (2014). Central nervous system control of food intake and body weight. Nature, 505(7482), 84–91.
• Ouchi, N., et al. (2011). Adipokines in inflammation and metabolic disease. Nature Reviews Immunology, 11(2), 85–97.
• Phelan, S. M., et al. (2015). Implicit biases and weight stigma among healthcare professionals. Obesity Reviews, 16(4), 319–326.
• Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in human body weight regulation. International Journal of Obesity, 34(S2), S47–S55.
• Ryan, D. H., et al. (2016). 2016 AACE/ACE guidelines for comprehensive obesity management. Endocrine Practice, 22(Suppl 3), 1–203.
• Shah, M., et al. (2021). Barriers to effective obesity care and strategies to overcome them. Obesity, 29(1), 1–10.
• Sonnenburg, E. D., & Sonnenburg, J. L. (2019). The ancestral and industrialized gut microbiome and implications for human health. Nature Medicine, 25(3), 389–402.
• Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects. Diabetes Care, 27(1), 155–161.
• Tomiyama, A. J., et al. (2018). How and why weight stigma drives the obesity “epidemic” and harms health. American Psychologist, 73(7), 1019–1031.
• Wharton, S., et al. (2020). Obesity in adults: a clinical practice guideline. CMAJ, 192(31), E875–E891.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.

SEO Tags: Dr. Alex Jimenez, Dr. Maria Cardenas, Integrative Care, Chiropractic Care, Functional Medicine, Weight Management, Obesity Treatment, GLP-1, tirzepatide, semaglutide, integrative chiropractic, weight bias, El Paso TX, Injury Medical Clinic, Holistic Health, Prediabetes, Type 2 Diabetes, Binge Eating Disorder, pharmacotherapy for obesity, pain and obesity, rehabilitation, personal injury care, satiety hormones, adipose inflammation, multidisciplinary obesity care, naltrexone bupropion, Vyvanse, weight loss medication, musculoskeletal health, nervous system function, internal medicine